Aragon Pharmaceuticals aragonpharm.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Aragon Pharmaceuticals is a small-molecule drug discovery company focused on developing medicines for the treatment of hormonally-driven cancers. These cancers eventually become resistant to existing 1st generation antihormonal therapies, and follow-up treatments are largely ineffective or toxic. The company's lead compound, ARN-509, is an antiandrogen undergoing a Phase I/II clinical trial in patients with progressive, advanced castration-resistant prostate cancer. In addition to ARN-509, Arago...Show all

Aragon Pharmaceuticals is a small-molecule drug discovery company focused on developing medicines for the treatment of hormonally-driven cancers. These cancers eventually become resistant to existing 1st generation antihormonal therapies, and follow-...Show all

Company (Acquired)

Phone: 858-334-4830

Fax: 858-334-4848

12780 El Camino Real
Suite 301
San Diego, 92130
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Aragon Pharmaceuticals $122M Aug 19, 2013
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Aragon Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
OrbiMed AdvisorsVenture CapitalNew York, New York, United StatesSeries D, Series C, Series B, Series A
Aisling CapitalPrivate EquityNew York, New York, United StatesSeries D, Series C, Series B
The Column GroupVenture CapitalSan Francisco, California, United StatesSeries D, Series C, Series B, Series A
Topspin Consumer PartnersPrivate EquityMamaroneck, New York, United StatesSeries D, Series C
venBIOVenture CapitalSan Francisco, California, United StatesSeries D
See all 5 investors

Competitors

Company Status Description Investors
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Crystalline forms of an androgen receptor modulator Dec 11, 2019 Sep 08, 2020 Patent
Processes for the preparation of a diarylthiohydantoin compound May 31, 2019 Jul 28, 2020 Patent
Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer Apr 30, 2018 Jul 07, 2020 Patent
Crystalline forms of an androgen receptor modulator Jul 10, 2019 Feb 11, 2020 Patent
Crystalline forms of an androgen receptor modulator Apr 15, 2019 Jan 07, 2020 Patent
See all 26 patents